Impact BioMedical Inc Dossier
Qualitative Analysis
Business overview
Impact BioMedical Inc. (NYSE American: IBO) is a specialized biotechnology holding company focused on the discovery, development, and licensing of innovative healthcare solutions. Operating primarily as an intellectual property (IP) incubator and licensing engine rather than a traditional end-to-end manufacturer, the company focuses on specialty biopharmaceuticals, antivirals, antimicrobials, and consumer healthcare products. Its core proprietary technologies include Linebacker (a platform of small molecule polyphenol compounds targeting oncology, inflammatory disorders, and neurology), Laetose (a functional sugar alternative designed to inhibit inflammatory and metabolic responses), Equivir (a novel blend of polyphenols with demonstrated antiviral effects), and 3F (a functional fragrance formulation with antimicrobial and insect-repellent applications). Impact BioMedical operates as a majority-owned subsidiary of DSS, Inc..
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic combination where Dr. Ashleys Limited will acquire Impact BioMedical through a reverse merger, creating a combined public entity traded on the NYSE American. The initiative aims to combine Dr. Ashleys' global pharmaceutical manufacturing and commercialization capabilities with Impact BioMedical's innovation-driven patent portfolio.
Expected impact: Accelerates the development and global commercialization of Impact BioMedical's core technologies (Linebacker, Equivir, 3F, and Laetose) while resolving going concern uncertainties through institutional backing.
Advancing and commercializing the company's four core patented technology platforms: 3F (antimicrobial/antiviral botanical fragrance), Linebacker (small molecule polyphenols for oncology/neurology), Equivir (antiviral blend), and Laetose (low-glycemic sugar substitute). This includes out-licensing partnerships, such as the ongoing collaboration with ProPhase Labs, Inc. for Equivir and Linebacker.
Expected impact: Generates licensing milestones, upfront payments, and royalty revenues from global markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Celios' advanced air purification technology to expand Impact BioMedical's portfolio of health and wellness solutions. The patented three-stage filtration system targets ultrafine particles and dangerous pathogens, creating a tangible product line with immediate revenue-generating potential.
Financial impact: Generated $32,000 in retail sales during 2025, offset by inventory impairment charges of approximately $419,000 at year-end.
Strategic Partnerships
High. ProPhase Labs is licensed to develop and commercialize the Equivir antiviral platform (initially as an OTC dietary supplement) and evaluate the Linebacker platform for solid tumors in oncology.
Terms: Potential to generate licensing milestones and royalty revenues upon successful commercialization and market launch.